Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO ...
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果